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background:  The persistence of resistant arterial hypertension (HT) is partially regulated by the renal sympathetic nervous system (SNS). 
Renal sympathetic denervation (RSD) represents an effective treatment option for certain patients with HT, in case of optimal medical 
treatment fails. Neuropeptide Y (NPY) is a neurotransmitter that is co-released with norepinephrine and is up regulated during increased 
sympathetic activity. The primary aim of the present study was to examine the effect of RSD on NPY, as a specific biomarker of the 
sympathetic activity. Further, the association between NPY levels changes and blood pressure reduction after RSD will be analyzed in this 
study.
Methods:  A total of 80 consecutive patients (age: 64.9y [±10.2]) undergoing RSD were included in this study. Response to RSD was 
defined as an office systolic blood pressure (SBP) reduction of >10 mmHg, 6 months after RSD. Venous serum samples for measurement 
of NPY were collected prior to and 6 months after RSD.
Results:  A significant reduction in the office SBP of 23.1 mmHg (SBP basline: 166.1 mmHg [SD: 8.8], p<0.001) was documented 6 months 
after RSD. In patients with elevated NPY values there was a significant reduction of the NPY serum levels, 6 months after RSD (baseline: 
3.17 ng/mL [IQR: 2.71; 3.86] vs. follow-up: 2.65 ng/mL [IQR: 1.99; 3.34], p<0.01). There was a significant correlation between baseline SBP 
and RSD-related systolic BP reduction (r =-0.62; p<0.001) and NPY baseline values and NPY serum level changes (r =-0.64; p<0.001) 
after 6-month follow-up. In addition, successful SBP reduction after RSD (responders) was associated with a significantly greater NPY level 
reduction when compared with BP non-responders.
conclusion:  In addition to the blood pressure reduction in response to RSD, this study demonstrates an effect of RSD on NPY, as a 
specific biomarker for the sympathetic activity. The association between RSD related changes in SBP and NPY levels provide further 
evidence of the effect of RSD on the SNS.
